Verkhovtseva A.A. —
Changes in the cytokine profile and its correction in dogs with bacterial dermatitis
– 2018. – ¹ 4.
– P. 25 - 30.
DOI: 10.7256/2453-8809.2018.4.28066 URL: https://en. nbpublish.com/library_read_article.php?id=28066
Read the article
One of the most frequent pathologies that a veterinarian encounters in practice is dermatitis of various etiologies. According to statistics, the number of visits of patients with dermatological diseases increases every year. One of the factors provoking the susceptibility of an animal to allergens is the current environmental conditions.Treatment of skin infections and allergies in domestic animals remains a problem that needs to be addressed. It is known that an important component of the pathogenesis of allergic dermatitis accompanied by further infectious, in particular bacterial dermatitis, is the cytokine factor. The aim of the work is to study the level of the main classes of cytokines in bacterial eczema and the effect of Apoquel on the change in these indicators.
TNFα, Eczema, Oclacitinib, dermatitis, immunity, interleukins, cytokines, Pyrogens, Allergy, Lymphocytes
Abramov V.V., Abramova T.Ya., Gontova I.A., Kozlov V.A., Markova E.V., Poveshchenko A.F., Rebenko N.M., Solov'eva I.G., Sorokin O.V. Zolotaya seriya natsional'nykh nauchnykh dostizheniy. Osnovy neyroimmunologii.-Moskva: 2004.-100 s.
Kozlov V.A. Gomeostaticheskaya proliferatsiya limfotsitov v aspekte immunopatogeneza razlichnykh zabolevaniy. // Immunologiya. 2006. T.27, ¹6. S. 378-382.
Ann Sophie Lønnberg, Claus Zachariae, and Lone Skov. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014; 7: 251–259.
Dhand A1, Aminoff MJ. The neurology of itch. Brain. 2014 Feb;137(Pt 2):313-22. doi: 10.1093/brain/awt158. Epub 2013 Jun 22.
Gonzales, AJ; Bowman, JW; Fici, GJ; Zhang, M; Mann, DW; Mitton-Fry, M (August 2014). "Oclacitinib (Apoquel®) Is a Novel Janus Kinase Inhibitor with Activity Against Cytokines Involved in Allergy". Journal of Veterinary Pharmacology and Therapeutics. 37 (4): 317–24.
Lenarczyk A., Le T.T., Drane D., Malliaros J., Pearse M., Hamilton R., Cox J., Luft